Vigadrone Powder, For Solution
Product Images NDC 0245-0556
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Vigadrone (NDC 0245-0556). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1. percent Reduction From Baseline In Seizure Frequency (Vigadrone 02)
Figure 2. percent Reduction From Baseline In Seizure Frequency (Vigadrone 03)
All People Who Take Vigadrone (Vigadrone 04)
This is a warning for individuals taking VIGADRONE, a medication that poses a risk of permanent vision loss. The risk increases based on the dosage of VIGADRONE taken daily and the duration of the medication regimen, and there is no way for healthcare providers to predict when vision loss may occur. Vision loss could happen shortly after beginning treatment or at any point during or after treatment.*
Supplies You Will Need To Mix 1 Dose Of Vigadrone: (Vigadrone 05)
Oral Syringe Detail (Vigadrone 06)
Figure A (Vigadrone 07)
Figure B (Vigadrone 08)
Figure C (Vigadrone 09)
Figure D (Vigadrone 0a)
Figure E (Vigadrone 0b)
Figure F (Vigadrone 0c)
Figure G (Vigadrone 0d)
Figure H (Vigadrone 0e)
Figure I (Vigadrone 0f)
Figure J (Vigadrone 10)
Ndc 0245-0556-50vigadrone® (vigabatrin) For Oral Solution500 mg50 Single-dose Packetsrx Only (Vigadrone 11)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.